The other variable under consideration is trial endpoints. Jakafi was approved based on a primary endpoint that measured spleen reduction. That would be fine for CYT387 too, but it wouldn't capture data on anemia benefit/transfusion independence -- the drug's key differentiating characteristic. YM Bio must be thinking of way to design its phase III studies with either primary or secondary endpoints that will allow it to get anemia benefit data into CYT387's label, if approved.
YM Bio is two to three years beyond Incyte in the myelofibrosis treatment market. To catch up, YM BIO needs to be bold and produce data from phase III studies that will give doctors a compelling reason to prescribe CYT387 over Jakafi.
While we wait for YM Bio to announce phase III plans or a partnership (or both), the company will be presenting updated data from earlier studies of CYT387 at December's American Society of Hematology annual meeting. We last got meaningful clinical data on CYT387 at last year's ASH meeting.
YM Bio has traded sideways for the past year. Even with the new cash raised by YM Bio in 2012, the company's $277 million market value is still small compared to Incyte's $2.3 billion. That valuation gap should narrow, although I've been saying the same thing for more than a year and it hasn't happened.
I'd be happy to address any substantive argument for why FDA will approve Ampligen, the chronic fatigue syndrome drug from Hemispherx Biopharma (HEB). So far, most of the responses to my column this week have been the "%^&* YOU, SHORT-SELLING SCUM!" variety. Funny but not very persuasive. Biotech trader @sheffstation believes the changing environment at FDA -- regulators more sympathetic to patients groups, taking a more proactive, friendly manner with regards to drug approvals -- works in Hemispherx's favor. Says Sheff: "A key point is that it took FDA only 13 days to accept the
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV